940911-03-5

Usage

Uses

Used in Organic Synthesis:
5-ethynylpicolinaldehyde serves as a building block in organic synthesis, where its reactive ethynyl group allows for the formation of new chemical bonds and the creation of a diverse array of compounds. Its utility in this field is due to the ease with which the ethynyl group can participate in various chemical reactions, facilitating the synthesis of complex organic molecules.
Used in Coordination Chemistry:
In coordination chemistry, 5-ethynylpicolinaldehyde is employed as a ligand for metal complexation. Its ability to bind to metal ions provides a means to create stable metal complexes with potential applications in catalysis, materials science, and as models for understanding biological systems that involve metal ions.
Used in Fluorescent Probes for Biological Studies:
5-ethynylpicolinaldehyde is known for its fluorescent properties, making it a useful fluorescent probe in biological research. Its fluorescence can be utilized to track and visualize specific biomolecules or cellular processes, providing insights into biological mechanisms and aiding in the development of new diagnostic and therapeutic strategies.
Used in Research and Industrial Settings:
5-ethynylpicolinaldehyde's versatility extends to both research and industrial applications. In research, it contributes to the advancement of chemical knowledge and the development of new methodologies. Industrially, it may be incorporated into the production of specialty chemicals, pharmaceuticals, or materials that leverage its unique chemical and physical properties.

Upstream product

• 650606-63-6 5-[2-(trimethylsilyl)ethynyl]pyridine-2-carbaldehyde 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 1244016-81-6 5-{[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]ethynyl}pyridine-2-carbaldehyde 
• 1312992-94-1 5,5′-[2,5-bis(decyloxy)-1,4-phenylene]bis(ethyne-2,1-diyl)dipicolinaldehyde 
• 1033705-77-9 (5-ethynylpyridine-2-yl)methanol 

Relevant academic research and scientific papers

A heterometallic macrocycle as a redox-controlled molecular hinge

The ability to modify the structure of nanoscopic assemblies in a controlled fashion is an important prerequisite for the creation of functional supramolecular systems. Here, we describe a heterometallic Pt2Cu2-macrocycle which behaves as a molecular hinge. A square-planar Pt(ii) complex with pendent 2-formylpyridine groups was synthesized and structurally characterized. Condensation of the complex with benzylamine followed by reaction with Cu(MeCN)4BF4 resulted in the formation of a rectangular Pt2Cu2-macrocycle. Upon chemical oxidation of the Cu centers, the macrocycle folds up to adopt a butterfly-like geometry in which the Pt centers approach each other. This process can be reversed by chemical reduction.

NOVEL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE 6 AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a new compound having an inhibitory activity of histone deacetylase 6 (HDAC6), stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof in the preparation of a drug, a pharmaceutical composition comprising them, a prophylactic or therapeutic method corresponding, and a method of preparing a new derivative 1,3,4-oxadiazole triazol, a novel compound having selective HDAC6 inhibitory activity being represented by the following chemical formula I.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Spin-dimer networks: Engineering tools to adjust the magnetic interactions in biradicals

Magneto-structural correlations in stable organic biradicals have been studied on the example of weakly exchange coupled models with nitronyl nitroxide and imino nitroxide spin-carrying entities. Here, heteroatom substituted 2,2′-diaza- and 3,3′-diaza-tolane bridged biradicals were compared with the hydrocarbon analogue, while a biphenyl model with its 2,2′-bipyridine counterpart. For a 3,3′-diazatolane bridge the torsional angle between the nitronyl nitroxides and the pyridyl rings increased heavily (～52-54°) leading to a smaller theoretical intra-dimer exchange coupling value. However, a very large antiferromagnetic coupling was obtained experimentally. This could be appropriately explained by the presence of dominating inter-dimer exchange between the molecules. For the bis(imino nitroxide) with tolane bridge a field induced ordered state between 1.8 to 4.3 T in AC-susceptibility measurements was observed. In terms of a Bose Einstein condensate (BEC) of triplons this phenomenon could be described as a magnetic field induced ordered phase with 3D character.

2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF

Provided in the present invention are a 2-arylbenzofuran-7-formamide compound as shown in general formula I or a pharmacologically or physiologically acceptable salt thereof, a preparation method thereof and use thereof in preparing anti-tumour drugs, whe

The discovery of polo-like kinase 4 inhibitors: Design and optimization of spiro[cyclopropane-1,3′[3H]indol]-2′(1′H).ones as orally bioavailable antitumor agents

Polo-like kinase 4 (PLK4), a unique member of the polo-like kinase family of serine-threonine kinases, is a master regulator of centriole duplication that is important for maintaining genome integrity. Overexpression of PLK4 is found in several human cancers and is linked with a predisposition to tumorigenesis. Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3′-indolin]-2′-ones reported herein. Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 X-ray structure and SAR attained from the analogous alkenelinked series. The racemic cyclopropane-linked compounds showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved physicochemical, ADME, and pharmacokinetic properties. Positive xenograft results from the MDA-MB-468 human breast cancer xenograft model for compound 18 support the investigation of PLK4 inhibitors as anticancer therapeutics. A PLK4 X-ray co-structure with racemate 18 revealed preferential binding of the 1R,2S enantiomer to the PLK4 kinase domain.

2-ARYLBENZOFURAN-7-FORMAMIDE COMPOUNDS, PREPARATION METHOD AND USE THEREOF

Provided in the present invention are a 2-arylbenzofuran-7-formamide compound as shown in general formula I or a pharmacologically or physiologically acceptable salt thereof, a preparation method thereof and use thereof in preparing anti-tumour drugs, whe

HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS

The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.